http://www.dmedicalindustries.com () —
D. Medical Industries Ltd. (NASDAQ: DMED)(TASE: DMDC) ("D. Medical" or
the "Company"), a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery, today
announced the appointment of Zoe H. Myers as the Company's Chief
Commercial Officer, effective February 1, 2011. Ms. Myers'
responsibilities will include leading global commercial strategy and
U.S. operations for D. Medical.
Ms. Myers is an international business leader with an accomplished
history of opening new markets for novel diabetes devices. She joins
D. Medical from her current position as Advisor at MC2 Consulting,
Inc., a consulting firm that manages the full product lifecycle,
including the development of business and marketing plans, for
emerging R&D companies.
Ms. Myers, 45, began her professional career in the diabetes device
space in 1994 as a Territory Manager for Disetronic AG, a world leader
in the research and development of insulin pumps and injection
systems. There, she progressed through a number of sales and
operations management positions and, at the time of Roche Diagnostics
Corporation's acquisition of Disetronic in 2003, was National Director
of North American Field Operations, managing 110 employees responsible
for sales, reimbursement and clinical services. Among many
accomplishments while with Roche, Ms. Myers played a key role in
securing Medicare reimbursement for insulin pump therapy. She served
two terms in a volunteer position with American Association for
Clinical Endocrinology ("AACE") as the Chair of the AACE Corporate
Advisory Board in 2001-03, and is a past board member of the Lawson
Wilkins Pediatric Endocrinology Society. Based on her success and
reputation in the diabetes industry, Ms. Myers was recruited in 2005
to join Exsulin, Inc., developer of a peptide-based drug in Phase II
clinical trials targeted at regeneration of insulin-producing islets
in patients with established Type 1 Diabetes. Ms. Myers served as
Exsulin's Vice President of Marketing and Strategic Communication
until joining MC2 Consulting in 2009. Ms. Myers is a graduate of the
School of Foreign Service at Georgetown University, with a Masters of
Science from Johns Hopkins University.
"We are very pleased to have attracted a leader of Zoe Myers' caliber
to this key position. Her extensive and demonstrable record of
accomplishment in commercializing new diabetes treatments and insulin
delivery devices will be a great asset for D. Medical going forward,"
commented Efri Argaman, D. Medical's Chief Executive Officer.
Zoe Myers said, "As D. Medical enters into the most exciting phase of
a company's development, I see my new role as driving the three A's of
any successful medical device roll out - Awareness, Acceptance and
Adoption. I am confident that the Company's innovative technology
portfolio, combined with the elegance of its design, will provide all
the tools we need to accomplish our commercial goals and objectives."
About D. Medical
D. Medical is a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery. D.
Medical has developed durable and semi-disposable insulin pumps, which
continuously infuse insulin into a patient's body, using its
proprietary spring-based delivery technology. D. Medical believes that
its spring-based delivery mechanism is cost-effective compared to the
motor and gear train mechanisms that drive competitive insulin pumps
and also allows it to incorporate certain advantageous functions and
design features in its insulin pumps. D. Medical has also developed an
infusion set for insulin pumps and is focusing its research and
development efforts on the development of next generation insulin
pumps and a device that will combine a continuous glucose monitoring
system and an insulin pump on the same patch. For more information,
visit http://www.dmedicalindustries.com
(http://www.dmedicalindustries.com) .
Forward-Looking Statements
This press release contains forward-looking statements (as defined by
the Israeli Securities Law, 1968, Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended) that involve risks and uncertainties. These
statements include, forecasts, goals, uncertainties and assumptions
and relate, inter alia, to D. Medical's future expectations in
connection with its level of sales and cost of sales, manufacturing
volumes, the cost-effectiveness of its spring-based design, target
markets and timing of markets penetration. The forward-looking
statements are based on D. Medical's current expectations and beliefs
which are based on, among other things, its analysis of publicly
available information and market research reports. All forward-looking
statements are subject to certain risks, uncertainties and assumptions
that could cause actual results to differ materially from those
described in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, the impact of general
economic conditions, competitive products, product demand, product
performance, the performance of D. Medical's contract manufacturer and
distributors, regulatory trends and approvals and healthcare reform
legislation. If one or more of these risks and/or uncertainties
materialize, or if the underlying assumptions prove to be incorrect,
D. Medical's actual results, performance or achievements could differ
materially from those expressed in, or implied by, any such
forward-looking statements or results which are based upon such
assumptions. No assurances can be given that any of the events
anticipated by the forward-looking statements will transpire or occur,
or of any of them will transpire or occur, what impact it will have on
D. Medical's results of operations or financial condition. D. Medicals
does not undertake to update any forward-looking statements.